BACKGROUND: Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation increases a drug's half life and exposure, and may also reduce immunogenicity. OBJECTIVE: The objective of this study was to characterize the incidence and impact of immunogenicity to peginterferon beta1a over 2 years in patients with MS. METHODS:Patients with relapsing-remitting MS (N = 1512) were randomized to subcutaneous peginterferon beta1a 125 μg every 2 or 4 weeks, or placebo, for 1 year; patients in the placebo group were rerandomized to active treatment in year 2. The incidence and titers of binding antibodies (BAbs) and NAbs to interferon and antibodies to PEG (anti-PEG) were assessed in analytically validated assays. The clinical impact of immunogenicity on relapse and magnetic resonance imaging endpoints was evaluated. RESULTS: Over 2 years, 6%, less than 1%, and 7% of patients developed anti-interferon BAbs, NAbs, and anti-PEG antibodies, respectively. There was no discernible clinically meaningful effect of antibody status on the pharmacodynamic, efficacy, or safety parameters evaluated, although these analyses were limited by the low incidence of treatment-emergent antibodies. CONCLUSION: The treatment effect of peginterferon beta1a in patients with relapsing-remitting MS is not expected to be attenuated by immunogenicity.
RCT Entities:
BACKGROUND: Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation increases a drug's half life and exposure, and may also reduce immunogenicity. OBJECTIVE: The objective of this study was to characterize the incidence and impact of immunogenicity to peginterferon beta1a over 2 years in patients with MS. METHODS:Patients with relapsing-remitting MS (N = 1512) were randomized to subcutaneous peginterferon beta1a 125 μg every 2 or 4 weeks, or placebo, for 1 year; patients in the placebo group were rerandomized to active treatment in year 2. The incidence and titers of binding antibodies (BAbs) and NAbs to interferon and antibodies to PEG (anti-PEG) were assessed in analytically validated assays. The clinical impact of immunogenicity on relapse and magnetic resonance imaging endpoints was evaluated. RESULTS: Over 2 years, 6%, less than 1%, and 7% of patients developed anti-interferon BAbs, NAbs, and anti-PEG antibodies, respectively. There was no discernible clinically meaningful effect of antibody status on the pharmacodynamic, efficacy, or safety parameters evaluated, although these analyses were limited by the low incidence of treatment-emergent antibodies. CONCLUSION: The treatment effect of peginterferon beta1a in patients with relapsing-remitting MS is not expected to be attenuated by immunogenicity.
Authors: Chris H Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Joep Killestein; Henry F McFarland; Joel Oger; Andrew R Pachner; John Petkau; Anthony T Reder; Stephen C Reingold; Huub Schellekens; Per Soelberg Sørensen Journal: Lancet Neurol Date: 2010-07 Impact factor: 44.182
Authors: C Ross; K M Clemmesen; M Svenson; P S Sørensen; N Koch-Henriksen; G L Skovgaard; K Bendtzen Journal: Ann Neurol Date: 2000-11 Impact factor: 10.422
Authors: F Matsuda; Y Torii; H Enomoto; C Kuga; N Aizawa; Y Iwata; M Saito; H Imanishi; S Shimomura; H Nakamura; H Tanaka; H Iijima; H Tsutsui; Y Tanaka; S Nishiguchi Journal: J Viral Hepat Date: 2012-05-29 Impact factor: 3.728
Authors: C Polman; L Kappos; R White; F Dahlke; K Beckmann; C Pozzilli; A Thompson; J Petkau; D Miller Journal: Neurology Date: 2003-01-14 Impact factor: 9.910
Authors: Raziye Mohammadpour; Marina A Dobrovolskaia; Darwin L Cheney; Khaled F Greish; Hamidreza Ghandehari Journal: Adv Drug Deliv Rev Date: 2019-07-08 Impact factor: 15.470
Authors: Rachel E Rau; ZoAnn Dreyer; Mi Rim Choi; Wei Liang; Roman Skowronski; Krishna P Allamneni; Meenakshi Devidas; Elizabeth A Raetz; Peter C Adamson; Susan M Blaney; Mignon L Loh; Stephen P Hunger Journal: Pediatr Blood Cancer Date: 2017-11-01 Impact factor: 3.167
Authors: Stanley L Cohan; Barry A Hendin; Anthony T Reder; Kyle Smoot; Robin Avila; Jason P Mendoza; Bianca Weinstock-Guttman Journal: CNS Drugs Date: 2021-07-06 Impact factor: 5.749
Authors: Scott D Newsome; Thomas F Scott; Douglas L Arnold; Gereon Nelles; Serena Hung; Yue Cui; Shulian Shang; Maria L Naylor; Marcelo Kremenchutzky Journal: Ther Adv Neurol Disord Date: 2018-08-28 Impact factor: 6.570